All In Biotech

Drug Trial Radar · NCT07125261

BHV-7000 Responsive Neurostimulation System (RNS) Study

BHV-7000 Efficacy Against Epileptiform Activity in Patients With Epilepsy Implanted With RNS

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Oct 7, 2025

Primary completion

Mar 18, 2026

Study completion Sep 16, 2026

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Biohaven Pharmaceuticals, Inc.
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label study to assess the biological effect of BHV-7000 on abnormal activity recorded by the RNS System in patients with focal epilepsy implanted with the RNS System. BHV-7000 is a potassium channel activator being evaluated for use in epilepsy. Participants are offered the drug for 4 weeks. Activity during that treatment period is compared to a 90-day retrospective baseline period in which other medications and device settings were stable, and also to a 4-week withdrawal period after treatment is discontinued. The study is open to patients with RNS regardless of whether they report clinical seizures, as long as the device recordings continue to show epileptiform activity.

Conditions

  • Epilepsy
  • Seizures

Interventions

  • BHV-700Drug

    75 mg daily for the 4-week treatment period (dose which may be adjusted based on tolerability)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in patient-specific seizure surrogate rateTime frame: 28 days
  2. Reduction in seizure onset pattern rateTime frame: 28 days
  3. Reduction in long episode rateTime frame: 28 days
  4. Reduction in saturation rateTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yale Comprehensive Epilepsy Center

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.